61049-67-0

Basic information

• Product Name: 3-(benzyloxy)-4H-pyran-4-one
• Synonyms: 3-(benzyloxy)-4H-pyran-4-one
• CAS NO: 61049-67-0
• Molecular Formula: C₁₂H₁₀O₃
• Molecular Weight: 202.206
• Mol File: 61049-67-0.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 409.4°C at 760 mmHg
• Flash Point: 193.1°C
• Appearance: /
• Density: 1.21g/cm³
• Vapor Pressure: 6.53E-07mmHg at 25°C
• Refractive Index: 1.585
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 3-(benzyloxy)-4H-pyran-4-one(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(benzyloxy)-4H-pyran-4-one(61049-67-0)
• EPA Substance Registry System: 3-(benzyloxy)-4H-pyran-4-one(61049-67-0)

Safety Data

• Hazardous Substances Data: 61049-67-0(Hazardous Substances Data)

Usage

General Description

3-(Benzyloxy)-4H-pyran-4-one is a chemical compound that falls under the category of organic compounds known as benzyloxy compounds, specifically those comprising a benzyl group involved in an O-aryl bond to benzene. It is a pyranone, a class of organic molecules characterized by a pyran ring bearing a ketone. It exists as a light yellow crystalline powder and its molecular formula is C14H12O3. This chemical is generally utilized in different fields, particularly in the synthesis of various pharmaceutical products for its propitious medicinal properties like antioxidant, anti-microbial, anti-inflammatory, and anti-cancer traits. It can be produced synthetically and isn't naturally occurring. Regarding its safety, it should be utilized with caution as it can trigger skin, eye, and respiratory irritation on exposure.

InChI:InChI=1/C12H10O3/c13-11-6-7-14-12(8-11)15-9-10-4-2-1-3-5-10/h1-8H,9H2

Upstream product

• 501-30-4 5-hydroxy-2-(hydroxymethyl)-4H-pyran-4-one 
• 100-39-0 benzyl bromide 
• 100-44-7 benzyl chloride 
• 15771-06-9 5-benzyloxy-2-hydroxymethyl-4H-pyran-4-one 
• 496-63-9 3-hydroxy-pyran-4-one 
• 1219-33-6 5-(benzyloxy)-4-oxo-4H-pyran-2-carboxylic acid 

Downstream Products

• 362598-68-3 3-benzyloxy-1-(2-piperidin-1-yl-ethyl)-1H-pyridin-4-one 
• 362598-71-8 3-benzyloxy-1-(2-morpholin-4-yl-ethyl)-1H-pyridin-4-one 
• 496-63-9 3-hydroxy-pyran-4-one 
• 1333331-84-2 3-[(4-methoxybenzyl)oxy]-4H-pyran-4-one 
• 1333331-85-3 3-[(4-methoxybenzyl)oxy]pyridin-4(1H)-one 
• 1333331-86-4 4'-iodo-3-[(4-methoxybenzyl)oxy]-4H-1,2'-bipyridin-4-one 
• 1333331-87-5 {3-[(4-methoxybenzyl)oxy]-4-oxo-4H-1,2'-bipyridin-4-yl}boronic acid 
• 1333331-88-6 3-[(4-methoxybenzyl)oxy]-4'-phenyl-[1,2']bipyridinyl-4-one 
• 1333331-89-7 6'-bromo-3-[(4-methoxybenzyl)oxy]-4H-1,2'-bipyridin-4-one 
• 1333331-90-0 3'-fluoro-4'-iodo-3-[(4-methoxybenzyl)oxy]-4H-1,2'-bipyridin-4-one 
• 1333331-91-1 4'-(5-chloro-1H-pyrrolo[2,3-b]pyridin-4-yl)-3'-fluoro-3-[(4-methoxybenzyl)oxy]-4H-1,2'-bipyridin-4-one 
• 1138-45-0 3-benzyloxy-4(1H)-pyridone 
• 1064077-34-4 3-benzyloxy-1-methyl-1H-pyridin-4-one 
• 362598-70-7 3-benzyloxy-1-[2-(1-methyl-pyrrolidin-2-yl)-ethyl]-1H-pyridin-4-one 

Relevant articles and documents

Rational design, synthesis and biological evaluation of novel multitargeting anti-AD iron chelators with potent MAO-B inhibitory and antioxidant activity

A series of (3-hydroxypyridin-4-one)-coumarin hybrids were developed and investigated as potential multitargeting candidates for the treatment of Alzheimer's disease (AD) through the incorporation of iron-chelating and monoamine oxidase B (MAO-B) inhibition. This combination endowed the hybrids with good capacity to inhibit MAO-B as well as excellent iron-chelating effects. The pFe3+ values of the compounds were ranging from 16.91 to 20.16, comparable to more potent than the reference drug deferiprone (DFP). Among them, compound 18d exhibited the most promising activity against MAO-B, with an IC50 value of 87.9 nM. Moreover, compound 18d exerted favorable antioxidant activity, significantly reversed the amyloid-β1-42 (Aβ1-42) induced PC12 cell damage. More importantly, 18d remarkably ameliorated the cognitive dysfunction in a scopolamine-induced mice AD model. In brief, a series of hybrids with potential anti-AD effect were successfully obtained, indicating that the design of iron chelators with MAO-B inhibitory and antioxidant activities is an attractive strategy against AD progression.

Systematic comparison of the mono-, dimethyl-and trimethyl 3-hydroxy-4(1H)-pyridones-Attempted optimization of the orally active iron chelator, deferiprone

A range of close analogues of deferiprone have been synthesised. The group includes mono-, di-and trimethyl-3-hydroxy-4(1H)-pyridones. These compounds were found to possess similar pFe3+ values to that of deferiprone, with the exception of the 2.5-dimethylated derivatives. Surprisingly the NHcontaining hydroxy-4(1H)-pyridones were found to be marginally more lipophilic than the corresponding N-Me containing analogues. This same group are also metabolised less efficiently by Phase 1 hydroxylating enzymes than the corresponding N-Me analogues. As result of this study, three compounds have been identified for further investigation centred on neutropenia and agranulocytosis.

Pyrones to pyrans: Enantioselective radical additions to acyloxy pyrones

This paper describes a highly site-, diastereo-, and enantioselective intermolecular radical addition/hydrogen atom transfer to hydroxypyrone pyromeconic and kojic acids. The methodology can be extended to the formation of chiral quaternary centers. The p